Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Elizabeth Kessler

Concepts (237)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Urinary Bladder Neoplasms
8
2026
259
2.870
Why?
Prostatic Neoplasms
14
2025
972
2.830
Why?
Carcinoma, Renal Cell
8
2023
231
1.860
Why?
Kidney Neoplasms
10
2023
419
1.840
Why?
Suicide, Assisted
6
2024
32
1.650
Why?
Antineoplastic Agents
11
2026
2219
1.580
Why?
Prostate-Specific Antigen
3
2021
162
1.240
Why?
Antineoplastic Combined Chemotherapy Protocols
7
2026
1998
0.980
Why?
Prostatic Neoplasms, Castration-Resistant
4
2026
54
0.950
Why?
Physicians
6
2024
955
0.920
Why?
Oncologists
2
2024
47
0.860
Why?
Patient Care Planning
1
2026
170
0.840
Why?
Patient Preference
1
2025
226
0.730
Why?
Aged
30
2026
26432
0.610
Why?
Orchiectomy
3
2016
72
0.600
Why?
Neoplasm Recurrence, Local
2
2018
1160
0.600
Why?
Anilides
5
2023
83
0.600
Why?
Euterpe
1
2018
4
0.570
Why?
Abiraterone Acetate
1
2017
15
0.500
Why?
Plant Extracts
1
2018
192
0.490
Why?
Neoplasms
7
2026
2954
0.490
Why?
Prednisone
1
2017
229
0.460
Why?
Capecitabine
1
2015
56
0.460
Why?
Indazoles
2
2014
86
0.460
Why?
Biliary Tract Neoplasms
1
2015
30
0.450
Why?
Pyridines
5
2023
610
0.450
Why?
Neoplasm Metastasis
6
2026
693
0.440
Why?
Frailty
1
2018
208
0.440
Why?
Humans
59
2026
146342
0.430
Why?
Imidazoles
2
2014
245
0.430
Why?
Neoplasms, Multiple Primary
1
2015
57
0.430
Why?
Carcinoma, Papillary
1
2015
83
0.420
Why?
Deoxycytidine
1
2015
219
0.420
Why?
Spinal Neoplasms
1
2014
36
0.420
Why?
Quinazolines
1
2015
267
0.410
Why?
Piperidines
1
2015
225
0.410
Why?
Testicular Neoplasms
3
2023
108
0.400
Why?
Immunotherapy
1
2018
671
0.380
Why?
Geriatric Assessment
5
2026
244
0.370
Why?
Medical Oncology
3
2026
345
0.360
Why?
Aged, 80 and over
9
2026
8391
0.340
Why?
Canada
5
2023
432
0.340
Why?
Male
32
2026
73396
0.340
Why?
Protein Kinase Inhibitors
2
2017
983
0.310
Why?
Carcinoma, Squamous Cell
1
2015
628
0.310
Why?
Surveys and Questionnaires
9
2025
6073
0.290
Why?
Neoplasms, Germ Cell and Embryonal
2
2023
76
0.290
Why?
Adaptation, Psychological
1
2014
721
0.280
Why?
Antibodies, Monoclonal, Humanized
2
2026
992
0.280
Why?
Aging
2
2018
1996
0.270
Why?
Androgen Antagonists
3
2020
91
0.270
Why?
Middle Aged
18
2026
36619
0.260
Why?
Age Factors
4
2026
3347
0.260
Why?
Palliative Care
4
2026
1032
0.250
Why?
Pancreatic Neoplasms
1
2015
944
0.250
Why?
Neoplasm Staging
5
2023
1488
0.250
Why?
Neoadjuvant Therapy
2
2021
475
0.250
Why?
Caregivers
2
2023
1080
0.250
Why?
Urothelium
3
2019
33
0.250
Why?
Communication
2
2024
980
0.240
Why?
Delphi Technique
2
2026
350
0.240
Why?
Carcinoma, Transitional Cell
2
2019
70
0.240
Why?
Neoplasm Invasiveness
2
2020
504
0.240
Why?
Malignant Atrophic Papulosis
1
2025
1
0.230
Why?
Treatment Outcome
8
2025
11821
0.230
Why?
Carboplatin
1
2026
168
0.230
Why?
Stress, Psychological
1
2014
1171
0.230
Why?
Phenylurea Compounds
1
2026
122
0.220
Why?
Quinolines
1
2026
191
0.210
Why?
Biopsy
3
2025
1075
0.200
Why?
Penile Neoplasms
1
2023
7
0.200
Why?
Subacute Care
1
2024
85
0.190
Why?
Terminally Ill
1
2023
40
0.190
Why?
Pilot Projects
5
2023
1888
0.190
Why?
Molecular Targeted Therapy
2
2018
447
0.180
Why?
Bone Neoplasms
2
2015
272
0.180
Why?
Administration, Oral
1
2025
872
0.180
Why?
Skilled Nursing Facilities
1
2024
152
0.180
Why?
Quality of Life
4
2022
3200
0.180
Why?
Female
18
2025
79499
0.170
Why?
Adenosine Deaminase
1
2021
45
0.170
Why?
Vasculitis
1
2021
69
0.170
Why?
Cross-Sectional Studies
3
2025
5899
0.170
Why?
Skin
1
2025
701
0.160
Why?
Lung Neoplasms
1
2014
2675
0.160
Why?
Antineoplastic Agents, Immunological
1
2023
200
0.160
Why?
Lupus Erythematosus, Systemic
1
2023
241
0.160
Why?
Videoconferencing
1
2020
62
0.160
Why?
Ureteral Neoplasms
1
2019
1
0.150
Why?
Nephroureterectomy
1
2019
2
0.150
Why?
Adult
11
2025
41087
0.150
Why?
Hospice Care
1
2022
230
0.150
Why?
Physical Examination
1
2020
237
0.150
Why?
Physician-Patient Relations
1
2024
597
0.140
Why?
Rheumatology
1
2020
136
0.140
Why?
Colorado
3
2024
4595
0.140
Why?
Fruit and Vegetable Juices
1
2018
23
0.140
Why?
United States
6
2025
16136
0.140
Why?
Pregnancy Complications, Neoplastic
1
2018
64
0.140
Why?
Patient Selection
2
2020
728
0.130
Why?
Frail Elderly
1
2018
141
0.130
Why?
Wilms Tumor
1
2018
91
0.130
Why?
Patient Discharge
1
2024
997
0.130
Why?
Attitude of Health Personnel
3
2024
1219
0.130
Why?
Proton Therapy
1
2017
16
0.130
Why?
Checklist
1
2018
105
0.120
Why?
Seminoma
1
2017
20
0.120
Why?
Prognosis
4
2023
4351
0.120
Why?
Taxoids
1
2017
115
0.120
Why?
Cancer Survivors
1
2022
348
0.120
Why?
Mass Screening
2
2021
1307
0.120
Why?
Nutritional Status
1
2018
346
0.120
Why?
Cisplatin
1
2018
347
0.120
Why?
Documentation
1
2018
202
0.120
Why?
Pneumonia, Viral
1
2020
387
0.110
Why?
Receptor Protein-Tyrosine Kinases
2
2021
227
0.110
Why?
Coronavirus Infections
1
2020
379
0.110
Why?
Clinical Decision-Making
1
2018
365
0.110
Why?
Radiation Tolerance
1
2015
101
0.110
Why?
Clinical Trials, Phase I as Topic
1
2014
49
0.100
Why?
Muscle, Smooth
1
2015
152
0.100
Why?
Decision Making
1
2022
993
0.100
Why?
Neoplasms, Complex and Mixed
1
2013
7
0.100
Why?
Patient Acceptance of Health Care
1
2020
881
0.100
Why?
Demography
1
2014
274
0.100
Why?
Carcinoma, Medullary
1
2013
16
0.100
Why?
Lymphatic Metastasis
1
2014
335
0.100
Why?
Risk Assessment
2
2023
3712
0.090
Why?
Angiogenesis Inhibitors
1
2014
239
0.090
Why?
Energy Metabolism
1
2018
930
0.090
Why?
Proto-Oncogene Proteins p21(ras)
1
2013
250
0.090
Why?
Psychiatric Status Rating Scales
1
2014
522
0.090
Why?
Pediatrics
1
2020
1124
0.090
Why?
Feasibility Studies
3
2023
1135
0.090
Why?
Bone Diseases
1
2012
60
0.090
Why?
Radiography
1
2014
861
0.090
Why?
Pandemics
1
2020
1707
0.090
Why?
Drugs, Investigational
1
2011
31
0.090
Why?
Clinical Competence
1
2020
1272
0.090
Why?
Needs Assessment
1
2014
404
0.080
Why?
Health Personnel
1
2018
754
0.080
Why?
Radiosurgery
1
2015
398
0.080
Why?
Urinary Bladder
1
2013
194
0.080
Why?
Telemedicine
1
2020
966
0.080
Why?
Gonadotropin-Releasing Hormone
1
2012
215
0.080
Why?
Cohort Studies
2
2026
6077
0.080
Why?
Sarcoma
1
2013
209
0.080
Why?
Antibodies, Monoclonal
1
2018
1512
0.080
Why?
Pyrimidines
1
2014
532
0.080
Why?
Disease Progression
1
2018
2867
0.080
Why?
Sulfonamides
1
2014
594
0.080
Why?
Practice Guidelines as Topic
1
2018
1591
0.080
Why?
Neoplasm Proteins
1
2013
444
0.080
Why?
Recombinant Fusion Proteins
1
2012
663
0.080
Why?
Tumor Suppressor Protein p53
1
2013
530
0.070
Why?
B7-H1 Antigen
2
2022
245
0.070
Why?
Quality Improvement
1
2018
1354
0.070
Why?
Survival Rate
3
2019
2092
0.070
Why?
Survival Analysis
2
2021
1378
0.060
Why?
Ataxia Telangiectasia Mutated Proteins
1
2026
69
0.060
Why?
Isoxazoles
1
2026
57
0.060
Why?
Pyrazines
1
2026
94
0.060
Why?
Nephrectomy
2
2018
172
0.050
Why?
Conscience
1
2024
9
0.050
Why?
Risk Factors
1
2018
10921
0.050
Why?
Drug Interactions
2
2017
405
0.050
Why?
Disclosure
1
2023
91
0.050
Why?
Retrospective Studies
4
2023
17438
0.050
Why?
Combined Modality Therapy
1
2025
1271
0.050
Why?
Telephone
1
2023
175
0.050
Why?
Morals
1
2023
84
0.050
Why?
SEER Program
1
2023
233
0.040
Why?
Young Adult
4
2023
14330
0.040
Why?
Severe Combined Immunodeficiency
1
2021
22
0.040
Why?
Agammaglobulinemia
1
2021
36
0.040
Why?
Multicenter Studies as Topic
1
2023
417
0.040
Why?
Adolescent
4
2025
22557
0.040
Why?
Intention to Treat Analysis
1
2021
78
0.040
Why?
Fatigue
1
2023
363
0.040
Why?
Prostate
1
2022
159
0.040
Why?
Intercellular Signaling Peptides and Proteins
1
2021
372
0.040
Why?
Follow-Up Studies
2
2022
5439
0.040
Why?
Europe
1
2020
421
0.040
Why?
Clinical Trials as Topic
2
2016
1064
0.040
Why?
Hospitals
1
2023
738
0.040
Why?
Neoplasm Grading
1
2019
313
0.030
Why?
Central Nervous System
1
2020
278
0.030
Why?
Survivors
1
2022
526
0.030
Why?
Disease-Free Survival
1
2019
778
0.030
Why?
Drug Administration Schedule
1
2019
790
0.030
Why?
Pain
1
2023
790
0.030
Why?
Betacoronavirus
1
2020
288
0.030
Why?
Proportional Hazards Models
1
2021
1331
0.030
Why?
National Cancer Institute (U.S.)
1
2017
56
0.030
Why?
Randomized Controlled Trials as Topic
1
2023
1763
0.030
Why?
Endothelial Cells
1
2021
876
0.030
Why?
Pregnancy Outcome
1
2018
503
0.030
Why?
Cognition
1
2023
1292
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2015
150
0.030
Why?
Radiotherapy, Intensity-Modulated
1
2015
143
0.030
Why?
Cytokines
1
2021
2081
0.020
Why?
Magnetic Resonance Imaging
2
2018
3926
0.020
Why?
beta-Galactosidase
1
2013
73
0.020
Why?
Delivery of Health Care
1
2020
947
0.020
Why?
Breeding
1
2013
64
0.020
Why?
Keratins
1
2013
57
0.020
Why?
Staining and Labeling
1
2013
148
0.020
Why?
Hyperplasia
1
2013
164
0.020
Why?
Tumor Stem Cell Assay
1
2012
33
0.020
Why?
Organ Specificity
1
2013
307
0.020
Why?
Integrases
1
2013
117
0.020
Why?
Fluorescent Antibody Technique
1
2013
345
0.020
Why?
Adenoviridae
1
2013
197
0.020
Why?
RNA, Untranslated
1
2013
125
0.020
Why?
Chemotherapy, Adjuvant
1
2013
429
0.020
Why?
Animals
4
2017
38107
0.020
Why?
Databases, Factual
1
2017
1493
0.020
Why?
Mutation
1
2021
4093
0.020
Why?
Xenograft Model Antitumor Assays
1
2012
930
0.020
Why?
Immunohistochemistry
1
2013
1712
0.020
Why?
ErbB Receptors
1
2012
636
0.020
Why?
Genotype
1
2013
1879
0.020
Why?
Dose-Response Relationship, Drug
1
2012
2022
0.020
Why?
Mice, Transgenic
1
2013
2134
0.020
Why?
Tomography, X-Ray Computed
1
2018
2786
0.020
Why?
Time Factors
1
2019
7109
0.020
Why?
Practice Patterns, Physicians'
1
2017
1408
0.020
Why?
Prospective Studies
1
2019
8123
0.020
Why?
Infant, Newborn
1
2018
6460
0.020
Why?
Biomarkers, Tumor
1
2013
1339
0.010
Why?
Pregnancy
1
2018
7230
0.010
Why?
Mice
2
2013
18297
0.010
Why?
Reproducibility of Results
1
2013
3416
0.010
Why?
Cell Proliferation
1
2012
2502
0.010
Why?
Cell Line, Tumor
1
2012
3545
0.010
Why?
Child
1
2023
22693
0.010
Why?
Disease Models, Animal
1
2012
4580
0.010
Why?
Kessler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)